HIV drug combining 3 medicines approved in U.S.: Knowledge Driven Revolution

Related - HIV = AIDS - Fact Or Fraud?

A once-a-day pill that combines three medicines for people with HIV has been approved in the U.S.

The pill, called Atripla, is a more convenient form of the pills people with HIV take to keep the virus in check.

Since the virus can become resistant to drugs when people skip pills or take medications at the wrong time, the combination treatment may help slow emergence of resistance.

Read the full article here

Article Continued...

"It's one thing to have medicine available, but it will only be effective when people can indeed take it as they are supposed to," U.S. Food and Drug Administration Deputy Commissioner Murray Lumpkin told reporters.

Atripla combines Viread (tenofovir), and Emtriva (emtricitabine), made by Gilead Sciences Inc., and Bristol-Myers Squibb Co.'s drug Sustiva (efavirenz).

The three drugs work to suppress HIV by blocking an enzyme the virus needs to replicate.

People with AIDS may still need to take other drugs to ward off infections and complications.

Atripla should be available in the U.S. in one week, the drugmakers said.

A month's supply will cost about $1,150 US.

Atripla's side-effects may include abnormal dreams, hallucinations and kidney problems. It can also cause birth defects.

Last month, the FDA approved another three-drug combination of generics to treat HIV in poor countries.

Broken Link? If the link to the original article is broken or has been altered you can view the article by clicking the "Expand/Collapse" button below.


HOME Articles by KDR V for Vendetta - R for Reality Canadian Bird Flu Pandemic Looming ? Shill of the Week: Stephan Harper Aspartame: The Sweetest Killer Chicken Little Terrorist of the Week: Creating Fake Terrorists Shill of the Week: Paul Martin The Number 1 Reason YOU became a Slave	HIV drug combining 3 medicines approved in U.S. CBC News July 14, 2006 Related - HIV = AIDS - Fact Or Fraud? A once-a-day pill that combines three medicines for people with HIV has been approved in the U.S. The pill, called Atripla, is a more convenient form of the pills people with HIV take to keep the virus in check. Since the virus can become resistant to drugs when people skip pills or take medications at the wrong time, the combination treatment may help slow emergence of resistance. Read the full article here Article Continued... "It's one thing to have medicine available, but it will only be effective when people can indeed take it as they are supposed to," U.S. Food and Drug Administration Deputy Commissioner Murray Lumpkin told reporters. Atripla combines Viread (tenofovir), and Emtriva (emtricitabine), made by Gilead Sciences Inc., and Bristol-Myers Squibb Co.'s drug Sustiva (efavirenz). The three drugs work to suppress HIV by blocking an enzyme the virus needs to replicate. People with AIDS may still need to take other drugs to ward off infections and complications. Atripla should be available in the U.S. in one week, the drugmakers said. A month's supply will cost about $1,150 US. Atripla's side-effects may include abnormal dreams, hallucinations and kidney problems. It can also cause birth defects. Last month, the FDA approved another three-drug combination of generics to treat HIV in poor countries. Broken Link? If the link to the original article is broken or has been altered you can view the article by clicking the "Expand/Collapse" button below. About KDR \| \| Home \| \| Weekly Features Archive	Weekly Weekly Features Archive
		In Depth What Is Wrong With Canada? Recent 9-11 News Suppressed by the Media Aspartame: The Sweetest Killer The Number 1 Reason YOU became a Slave Knowledge Driven Look at Your Favourite Canadian Political Parties
		Archive May June July 2006 25 26 27 28 29 30 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 01 02 03 04 05 Weekly Features 2006 2005 Read Today's Knowledge Driven News
		Counter
Copyright © 2005-6 KnowledgeDrivenRevolution.com

Articles by KDR

HIV drug combining 3 medicines approved in U.S.

Weekly

In Depth

Archive